item management s discussion and analysis of financial condition and results of operations results of operations the following discussion and analysis should be read in conjunction with the company s financial statements and related notes appearing elsewhere in this report 
consolidated net income for was million compared to  in and a net loss of million  on a restated basis  in diluted earnings per share increased from a net loss of in  on a restated basis  and a profit of in  to net income of in for the year ended  shares outstanding on a diluted basis were million  up from and million at year end and  respectively 
revenues consolidated revenues in totaled million  representing an increase of over revenues of million  which were over revenues of million 
inovoject r revenues totaled million in compared to million in and million in  representing increases of from to  and from to  with the increase coming principally from increased placement and throughput of inovoject r systems in north america and europe 
the revenues include inovoject r lease fees derived from multi year contracts and paid trials in the us and foreign countries  and the sale of inovoject r systems to distributors 
at december   embrex had over inovoject r systems installed and operating under lease agreements worldwide  up from over systems at december   and at december  additionally  embrex estimates that as of december   it was vaccinating in excess of of the estimated billion broiler birds grown in the us in  as well as approximately in  and in given its market penetration  the company expects only moderate inovoject r systems revenue growth in this market 
management anticipates moderate revenue and earnings growth in from existing inovoject r operations in the united states and canada  new inovoject r system leases in other countries  and sales of bursaplex tm product to poultry producers 
however  the rate at which the marketplace will accept the inovoject r technology outside the united states and canada  the timing of regulatory approvals of third party vaccines for in ovo use outside the united states and canada  start up costs in new markets  possible variability in us hatchery bird production as a result of grain price fluctuations  and possible variability in the demand for us poultry and poultry products outside the us  will impact the pace of revenue growth  if any  and the sustaining of profitability from the installation and operational throughputs of inovoject r systems 
in any event  any revenue and earnings growth in is not anticipated to begin prior to the third and fourth quarters 
sales of bursaplex tm  the company s proprietary vaccine for the treatment of avian infectious bursal disease  was the principal source of million of product revenues in the previously discussed delay associated with obtaining uk regulatory approval for the sale of bursamune tm in the uk reduced the sale of the company s proprietary vnf r product  which is a key component of bursamune tm  to ft 
dodge animal health  a division of american home products corp 
see business existing products  above 
this offset initial sales of bursaplex tm during and consequently resulted in a  decrease in product revenue from sales of vnf r for inclusion in ibd vaccines were the principal source of previous years product revenues  which generated million and  in and  respectively 
cost of product sales and inovoject r revenues cost of revenues as a percentage of revenues decreased from and of total revenues in and  respectively  to of total revenues in the improvement in is primarily attributable to inovoject r system related cost reductions 
operating expenses operating expenses totaled million in compared to million in  and million in general and administrative g a expenses were million in  up from million in  and up from million in the g a increase was primarily attributable to development costs in asia and latin america as well as legal expenses incurred in connection with various patent infringement lawsuits filed by the company 
the increase over was largely due to increased legal expenses associated with the implementation of a shareholder rights plan in march and amendments to the company s articles of incorporation approved at the annual meeting of shareholders in may sales and marketing expenses totaled  in compared to  and  in and  respectively 
fluctuations during these periods resulted from various levels of activity in the company s sales and customer service functions to support market expansion and field support of inovoject r systems  as well as stepped up international activity  principally in europe 
certain   and operating expenses were reclassified to cost of revenues to conform to the presentation format adopted in the fourth quarter of and during these reclassifications had no effect on previously reported net income or loss or shareholders equity in   or research and development r d expenses were million in compared to million in and million in the increase in r d expense from to largely reflects an increase in outside contract research  supplies consumption  and inovoject r design and development activity 
the company continues to manage its research and development effort to leverage its know how  patent position  market presence and expenditures 
other income and expense interest income totaled   and  in years   and  respectively 
the increase relative to resulted principally from higher cash balances  while the decrease in relative to was a function of lower interest rates 
interest expense totaled million in compared to million in  and million  on a restated basis  in in  the decrease in interest expense reflected the repayment of approximately million of external financing  primarily in the form of equipment leases 
in and  the amount of expense was principally attributable to the company s funding of its growing installed base of inovoject r systems with the use of capital lease financing and  in  the issuance of convertible debentures 
additionally  interest expense for has been restated to reflect a one time charge associated with recognizing  of interest expense attributable to the difference between the market price of the company s common stock and the conversion price of the debentures issued in see liquidity and capital resources and note to the company s financial statements 
management expects to continue to rely on the use of internally generated funds to finance the cost of additional inovoject r systems in  as was the case in effect of inflation management expects cost of product sales and inovoject r systems revenues  operating expenses and capital equipment costs to change in line with periodic inflationary changes in price levels 
while management generally believes that the company will be able to offset the effect of price level changes by adjusting selling lease prices and effecting operating efficiencies  any material unfavorable changes in price levels could have a material adverse affect on its results of operations 
year issue embrex s general ledger and primary financial accounting software is a dos based application that operates on a client server network 
this application uses only two digits to identify a year in the date field 
the company intends to replace this application during with a windows tm based system 
irrespective of the year issue  the company needs to upgrade its accounting system to meet the demands of its business 
the company is in the process of developing the implementation plan for this upgrade 
the company believes that the additional costs associated with the year aspects of the upgrade will be immaterial 
liquidity and capital resources at december   the company s cash and short term investment balances totaled million compared to million and million at december  and  respectively 
the decrease reflected the ability of the company to fund capital expenditures with internal cash instead of equipment lease financing 
working capital remained unchanged at million in both and  as a decrease in cash was offset by a reduction in the short term portions of both capital lease obligations and long term debt 
during  operating activities generated million in cash  primarily due to non cash depreciation  and net income 
within investing activities  inovoject r systems  the company s new research and testing facility  and equipment purchases required million  while the sale of short term investments  provided an offsetting million 
in addition  million was used to repay long term debt and capital lease obligations 
during   of outstanding debentures along with  of accrued interest were converted into  shares of common stock net of unamortized debt issuance costs totaling  in addition  shares of embrex common stock were issued pursuant to the non cash exercise of warrants related to the initial sale of the debentures in may as of december   all debentures had been converted into common stock 
as of december   the company had outstanding purchase commitments of approximately million related to the production of the company s bursaplex tm product  and materials and supplies for construction and maintenance of inovoject r egg injection systems 
this commitment included the obligation related to a january agreement reached with select laboratories  requiring the company to purchase all existing inventories of raw materials  bursaplex tm  and related materials from select within months following the january receipt of in ovo approval of the bursaplex tm product being manufactured for embrex 
in january  the company fulfilled its obligation to select under the january agreement 
the company maintains a million secured line of credit with a bank in the united kingdom  which may be used to finance the construction of additional inovoject r systems for europe  the middle east and africa 
the company utilized million of this line in  with the balance of available at year end 
a remaining commitment of million for utilization by embrex under a collaterized equipment financing arrangement expired in june based on its current operations  management believes that its available cash and short term investments  together with cash flow from operations  will be sufficient to meet its foreseeable cash requirements 
forward looking statements information set forth in this annual report on form k contains various forward looking statements within the meaning of section a of the securities act of and section e of the securities exchange act of  which statements represent the company s judgment concerning the future and are subject to risks and uncertainties that could cause the company s actual operating results and financial position to differ materially 
such forward looking statements can be identified by the use of forward looking terminology such as may  will  expect  anticipate  estimate  believe  or continue  or the negative thereof or other variations thereof or comparable terminology 
the company cautions that any such forward looking statements are further qualified by important factors that could cause the company s actual operating results to differ materially from those in the forward looking statements  including without limitation the company s ability to penetrate new markets  the company s dependence on certain customers  the ability of the company  its manufacturing and marketing partners and others to obtain regulatory approval for products  which is dependent on a number of factors  including the results of trials  the discretion of regulatory officials  and any potential changes in regulations  the company s ability to generate future cash flow from operations  continued demand for the inovoject r system  the successful outcome of patent litigation  the risk factors described in exhibit to this report  and other risks detailed from time to time in the company s securities and exchange commission filings  including the company s forms q  k  and k 

